| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/13/2002 | EP0946157B1 The topical use of kappa opioid agonists to treat ocular pain |
| 03/13/2002 | EP0874634B1 Control of healing process |
| 03/13/2002 | EP0845989B1 Pain-alleviating drug composition |
| 03/13/2002 | EP0841909B1 Use of alicyclic diamines as immunomodulators |
| 03/13/2002 | EP0673652B1 Biologically active agent having immunomodulating properties, method for its obtaining and pharmaceutical preparation based on it |
| 03/13/2002 | CN1340044A Nervinolin derivatives |
| 03/13/2002 | CN1339970A Anticancer agent potentiators |
| 03/13/2002 | CN1339969A Liposone composition and method for administration of a radiosensitizer |
| 03/13/2002 | CN1080562C Use of prostance derivatives and the combination with antibiotics in the treatment of bacterial infections |
| 03/12/2002 | US6356845 Crystallization and structure determination of Staphylococcus aureus UDP-N-acetylenolpyruvylglucosamine reductase (S. aureus MurB) |
| 03/12/2002 | US6355805 β3-adrenergic receptor agonists |
| 03/12/2002 | US6355690 Remedy for CAG repeat expansion diseases |
| 03/12/2002 | US6355684 Antimicrobial treatment for herpes simplex virus and other infectious diseases |
| 03/12/2002 | US6355681 Glycine substitutes and precursors for treating a psychosis |
| 03/12/2002 | US6355680 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies |
| 03/12/2002 | US6355661 Methods for treatment of sickle cell anemia |
| 03/12/2002 | US6355656 Phenidate drug formulations having diminished abuse potential |
| 03/12/2002 | US6355645 4-(3'-bromobenzoyl)-6,7-dimethoxyquinazoline; for lowering blood cholesterol, including reducing total cholesterol and ldl-cholesterol levels |
| 03/12/2002 | US6355628 Combination therapy using pentafluorobenzenesulfonamides |
| 03/12/2002 | US6355609 Methods for stabilizing liquid nutritional products and products so stabilized |
| 03/12/2002 | US6355480 Nucleotide sequences which code preferential protein for use in the treatment of fertility and cell proliferation defects |
| 03/12/2002 | US6355463 UDP-N-acetylenolpyruvylglucosamine reductase |
| 03/12/2002 | US6355460 Detecting enzyme inhibitors; incubate enzyme with modulator, monitor sample for reduction in enzyme activity, reduction in enzyme activity indicates modulator |
| 03/12/2002 | US6355451 Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 03/12/2002 | US6355426 Methods for the characterization and selection of RNA target motifs that bind compounds of pharmaceutical use |
| 03/12/2002 | US6355411 Virulence-associated nucleic acid sequences and uses thereof |
| 03/12/2002 | US6355268 Liposome-entrapped topoisomerase inhibitors |
| 03/12/2002 | US6355248 Method of modulating an immune response in an infected mammal by transmucosal administration of modulating agent |
| 03/12/2002 | CA2235625C Bactericidal/permeability increasing protein (bpi) for treating conditions associated with corneal transplantation |
| 03/07/2002 | WO2002019213A2 Method for treatment of migraine using pde5 inhibitors |
| 03/07/2002 | WO2002018938A1 Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases |
| 03/07/2002 | WO2002018637A2 Diagnosis and treatment of prostate cancer |
| 03/07/2002 | WO2002018608A2 Methods for enhancing the efficacy of cancer therapy |
| 03/07/2002 | WO2002018593A2 Modulation of fas and fasl expression |
| 03/07/2002 | WO2002018583A2 Modified polypeptides stabilized in a desired conformation and methods for producing same |
| 03/07/2002 | WO2002018581A2 G-protein coupled receptors |
| 03/07/2002 | WO2002018576A2 Compositions and methods relating to lung specific genes |
| 03/07/2002 | WO2002018572A2 Membrane penetrating peptides and uses thereof |
| 03/07/2002 | WO2002018557A2 Human kinases |
| 03/07/2002 | WO2002018554A2 Isolated human drug-metabolizing proteins, nucleic acid moleculesand uses thereof |
| 03/07/2002 | WO2002018553A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 03/07/2002 | WO2002018450A1 New cross-linked derivatives of hyaluronic acid |
| 03/07/2002 | WO2002018448A2 Percarboxylated polysaccharides, and a process for their preparation |
| 03/07/2002 | WO2002018445A2 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| 03/07/2002 | WO2002018444A2 Erbb4 antagonists |
| 03/07/2002 | WO2002018440A1 Anti-angiogenic peptides |
| 03/07/2002 | WO2002018369A2 Peptidomimetic protease inhibitors |
| 03/07/2002 | WO2002018368A1 Tricyclic antitumor compounds being farnesyl protein transferase inhibitors |
| 03/07/2002 | WO2002018346A1 Pyrazole derivatives and their use as protein kinase inhibitors |
| 03/07/2002 | WO2002018340A1 GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS |
| 03/07/2002 | WO2002017963A2 Modulators of intermediate conductance calcium-activated potassium (ikca) channel activity for treating sexual dysfunction |
| 03/07/2002 | WO2002017949A2 Novel functions for dp214 |
| 03/07/2002 | WO2002017939A1 A composition comprising pharmaceutical/nutraceutical agent and a bio-enhancer obtained from glycyrrhiza glabra |
| 03/07/2002 | WO2002017933A1 Trace elements |
| 03/07/2002 | WO2002017930A2 Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| 03/07/2002 | WO2002017929A1 Treatment of urinary dysfunction |
| 03/07/2002 | WO2002017927A1 Method for treating erectile dysfunction and increasing libido in men |
| 03/07/2002 | WO2002017923A1 Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors |
| 03/07/2002 | WO2002017906A1 Composition and method for treatment of hypertriglyceridemia |
| 03/07/2002 | WO2002017904A1 Use of asiatic acid or asiaticoside for treatment of cancer |
| 03/07/2002 | WO2002017899A2 Regulation of angiogenesis via modulation of edg receptor mediated signal transduction comprising sphingosine-1-phosphate administration |
| 03/07/2002 | WO2002017898A2 Compositions and methods for inducing vasorelaxation |
| 03/07/2002 | WO2002017895A2 Use of an aldosterone receptor antagonist to improve cognitive function |
| 03/07/2002 | WO2002017893A2 Sgk2 and sgk3 used as diagnostic and therapeutic targets |
| 03/07/2002 | WO2002017891A2 Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency |
| 03/07/2002 | WO2002017880A2 Nitric oxide-producing hydrogel materials |
| 03/07/2002 | WO2002017878A1 Lung surfactant compositions with dynamic swelling behaviour |
| 03/07/2002 | WO2002017858A2 Role of fosb in bone formation |
| 03/07/2002 | WO2002017857A2 Methods and compositions for inhibiting angiogenesis |
| 03/07/2002 | WO2002017855A2 Process for preparing pharmaceutical compositions for use with soft gelatin formulations |
| 03/07/2002 | WO2002017853A2 Hyaluronan-based antiadhesion compositions, their preparation and use |
| 03/07/2002 | WO2002017831A2 Devices for intraocular drug delivery |
| 03/07/2002 | WO2002017789A2 Methods and devices for quantitative analysis of x-ray images |
| 03/07/2002 | WO2002017735A2 Method for preparing a mixture that can be granulated and carnitine-magnesium hydroxycitrate |
| 03/07/2002 | WO2002017713A1 Collagen/polysaccharide bilayer matrix |
| 03/07/2002 | WO2001094420B1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 03/07/2002 | WO2001093911A3 Macromolecular drug complexes and compositions containing the same |
| 03/07/2002 | WO2001089457A3 Thrombopoietin mimetics |
| 03/07/2002 | WO2001079269A3 Lipid binding protein 4 |
| 03/07/2002 | WO2001070176A3 Use of 3,4-dihydroxy-mandelic acid for protecting against oxidative damage caused by ultra-violet light |
| 03/07/2002 | WO2001068122A3 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity 'mia' |
| 03/07/2002 | WO2001062765A3 Small molecule modulators of g protein-coupled receptor six |
| 03/07/2002 | WO2001062236A3 New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |
| 03/07/2002 | WO2001060407A3 Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis |
| 03/07/2002 | WO2001058956A3 Antibodies that bind human interleukin-18 and methods of making and using |
| 03/07/2002 | WO2001058949A3 Heterologous polypeptide of the tnf family |
| 03/07/2002 | WO2001057022A3 Pyrazole compositions useful as inhibitors of erk |
| 03/07/2002 | WO2001055692A3 Neurosteroids as markers for alzheimer's disease |
| 03/07/2002 | WO2001055178A3 Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer |
| 03/07/2002 | WO2001055092B1 5-aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents |
| 03/07/2002 | WO2001053468A3 Lipid metabolism enzymes and polynucleotides encoding them |
| 03/07/2002 | WO2001051636A3 Secreted proteins |
| 03/07/2002 | WO2001051040B1 Osmotic device containing alprazolam and an antipsychotic agent |
| 03/07/2002 | WO2001044808A3 Methods of diagnosis and treatment by binding p75/airm1 |
| 03/07/2002 | WO2001043761A3 Methods for treating and preventing damage to mucosal tissue |
| 03/07/2002 | WO2001042285A3 Extracellular matrix and cell adhesion proteins as well as genes encoding them |
| 03/07/2002 | WO2001036686A3 Genomic polymorphism for predicting therapeutic response |
| 03/07/2002 | WO2001032888A3 Human transferase molecules |
| 03/07/2002 | WO2001028591A3 Injection vehicle for polymer-based formulations |
| 03/07/2002 | WO2001021163A3 Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents |